ANNX Stock Analysis: Buy, Sell, or Hold?
ANNX - Annexon, Inc. Common Stock
$5.07
-0.11 (-2.12%)
âŧ
5d:
-4.16%
30d:
-4.34%
90d:
-6.8%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 20, 2026 at $5.18 · last confirmed Aug 21, 2026
Strength: 6.0/10
Get Alerted When ANNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ANNX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ANNX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ANNX is currently trading at $5.07, which is considered slightly low relative to its 30-day fair value range of $5.07 to $5.68.
Technical Outlook: Technically, ANNX is in a downtrend. The price is currently testing key support at $5.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ANNX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.71 (+190.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ANNX is in a downtrend. The price is currently testing key support at $5.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ANNX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.71 (+190.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.07 -
$5.68
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 190.2% below Wall St target ($14.71)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.07 -
$5.68
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.00
Resistance Level
$5.59
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.67
Wall Street Target
$14.71
(+190.2%)
Share & Embed Analysis
Last updated: August 23, 2026 1:34 AM ET
Data refreshes hourly during market hours. Next update: 2:34 AM
Data refreshes hourly during market hours. Next update: 2:34 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANNX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
William H Carson
BUY
8000 shares
2026-04-10
William H Carson
BUY
8000 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 42 HOLD |
